An interventional study of nephrectomy in Kidney Cancer, sponsored by Institut Paoli-Calmettes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Institut Paoli-Calmettes · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Kidney Neoplasms with a site in France — 31 open to participants now, 36 under way, 4 of them phase 3. Kidney Neoplasms · France.
Among the 108 studies in Kidney Neoplasms with a site in France, this one is the 50th largest by planned enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2026, is one of 28 with no phase, reaches primary completion later than 32 of the 35 other live ones, and was the 99th registered.
969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.
Browse Kidney Neoplasms studies →31 of the 108 studies in Kidney Neoplasms with a site in France are open now. Recruiting first, the newest first:
Mark C Burgmans, MD PhD · Sites in France, Netherlands
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
European Organisation for Research and Treatment of Cancer - EORTC · Sites in France
Ages 18–100
Bristol-Myers Squibb · Sites in France, United States, Canada and 2 more countries
Ages 18+
Centre Francois Baclesse · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 26 · Phase 3 15 · Phase 4 3
First in 1993; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 46 across 668 interventional studies indexed under Kidney Neoplasms.
Median enrollment 100 across the 78 interventional studies, 163 across the 30 observational. Of the 58 that completed or were terminated, 17 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 108 have an industry lead sponsor. The 10 most frequent:
Institut Paoli-Calmettes is the lead sponsor of 172 studies on the registry; 50 are open to participants now.
Institut Paoli-Calmettes has 2 studies filed under Kidney Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03185039Institut Paoli-CalmettesPredictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents | 2026-12-19 |
| NCT07739121Assistance Publique - Hôpitaux de ParisBenchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations | 2026-12-31 |
| NCT06026410Kura Oncology, Inc.KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | 2027-01 |
| NCT05433142Xencor, Inc.Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | 2027-02 |
| NCT05241561Centre Hospitalier Universitaire de BesanconCabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients | 2027-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 108 studies in Kidney Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the current era of immune checkpoint inhibitors (ICI), the role and timing of nephrectomy remains unknown, particularly in cases of residual kidney disease after a major response at metastatic sites. In these cases, the rationale for a delayed nephrectomy is that it might achieve a long-term response. This strategy could allow some patients to discontinue treatment and maintain tumor response. Furthermore, this approach might provide a potentially curative option for patients with metastases that are managed with and responding to ICI.
Regarding the results of our first retrospective cohort data (showing that two thirds of patients are free from recurrence without systemic treatment after nephrectomy), we designed a non-comparative randomized phase II trial assessing progression-free survival of patients with complete response or major partial response after ICI-based treatment, operated on delayed nephrectomy with discontinuation of systemic therapy (experimental arm) and in patients managed with continuation of systemic therapy without nephrectomy (control arm).
In a de-escalation approach, this strategy may have sense to allow patients with an excellent response to immunotherapy to stop systemic treatment with a curative objective and a substantial impact from a medico-economic point of view.
Patients with metastatic kidney cancer will be treated according to current first-line treatment guidelines.
Patients may be included in the study (by signing a consent form) and randomized if a complete response (CR) or metastatic partial response (mPR) (>75%) is achieved with immunotherapy-based systemic therapy.
In the centers participating in the ancillary study, patients in the experimental arm (arm A) will undergo renal MRI and PSMA PET (positron emission tomography) scan prior to nephrectomy.
Arm A patients will undergo nephrectomy (partial or enlarged, depending on technical possibilities and surgeon's discretion), after which systemic treatment will be discontinued.
Patients in arm B will not undergo surgery, and will continue their systemic treatment unchanged (interrupted in the event of toxicity, in accordance with current recommendations).
In both arms, follow-up will consist of a biological and CT scan evaluation every 3 months for 2 years.
The primary objective is to evaluate the efficacy of the experimental strategy in terms of progression-free survival, progression being defined according to the usual RECIST criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
delayed nephrectomy and discontinuation of systemic treatment
Procedure: nephrectomy
no nephrectomy and continuation of systemic treatment
Nephrectomy scheduled within 3 months of inclusion. Patients may continue their systemic treatment at the usual rate until D-5 prior to surgery. Treatment will not be resumed after surgery. Surgery may consist of partial or enlarged nephrectomy, with or without associated lymph node dissection, depending on technical possibilities and at the surgeon's discretion.
progression-free survival
post-randomization progression-free survival
Time frame: 24 month
Overall survival
Overall post-randomization survival
Time frame: 24 month
Intraoperative and postoperative complications
Rate of intraoperative and postoperative complications
Time frame: 30 days
Immunotherapy-related adverse events
Rate of immunotherapy-related adverse events (including CTCAE grade ≥ 3)
Time frame: 24 months
Started May 2026 (actual). Primary completion is estimated for Apr 2031, 59 months after the start.
Of 90 non-industry interventional studies with no phase under Kidney Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 94. This study's planned 59 months is above that.
Counting every sponsor, half of 97 studies reached it within 42 months; a quarter within 21 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.